Adipo Therapeutics' lead asset, ADPO-007NP, is a first-in-class Notch-inhibitor nanoparticle technology that is designed as a localized, weekly treatment that browns white adipose tissue to create adipose tissue that is metabolically active and systemically draws excess lipids and glucose to it for energy consumption.  Animal studies have demonstrated that the localized increase in brown fat leads to durable weight loss, improved blood glucose control, and a decrease in lipids with no change in calorie intake. Unlike current treatments Adipo increases energy expenditure with local delivery into the intracellular matrix of the white adipose thereby potentially limiting off target impacts and side effects. ADPO-007NP is being developed to be in combination with low dose GLP-1s and as a monotherapy for whom the core defect driving the obesity is a low resting metabolic rate.